Ensayo clínico

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT: NCT04559685 · TERMINATED

ID NCTNCT04559685

EstadoTERMINATED

Fecha de inicio2021-03-15

Finalización2024-11-10

SponsorNader Sanai (OTHER)

First posted2020-09-23

Last updated2026-05-14

Resumen breve

A Phase 0 single center, first in human, open-label study of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety and efficacy in up to 45 participants with recurrent HGG. Eligible participants who are scheduled for resection will be administered intravenous (IV) aminolevulinic acid HCl (ALA) approximately six to seven (6-7) hours prior to receiving sonodynamic therapy (SDT).

Fuente oficial

Ver en ClinicalTrials.gov →

Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.